SCHEMBL6420048

SCHEMBL6420048

O=C(Nc1ccc(NC(=O)c2c(Cl)cc(Cl)cc2Cl)c2c1C(=O)c1ccccc1C2=O)c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.66
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MMP14 P50281 1/20 0.54
CYP1A2 P05177 1/20 0.51
TSHR P16473 1/20 0.51
TERT O14746 3/20 0.46
MAOA P21397 1/20 0.45
CASP3 P42574 1/20 0.45
KDM4E B2RXH2 2/20 0.44
RXFP1 Q9HBX9 2/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NSD2 O96028 1/20 0.44
POLB P06746 1/20 0.44
BLM P54132 1/20 0.44
TTR P02766 1/20 0.44
HSPA5 P11021 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418987 0.85 TP53 (0.57) PTPRCMEN1KMT2ACASP3KDM4E
SCHEMBL6421532 0.81 CASP3 (0.65) MEN1KMT2AMMP14CYP1A2CASP3
SCHEMBL6424210 0.81 MEN1 (0.60) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL9846545 0.80 KMT2A (0.59) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL6263284 0.80 PTPRC (1.00) PTPRCMEN1KMT2ACYP1A2TSHR
SCHEMBL11301981 0.79 KMT2A (0.50) PTPRCMEN1KMT2AMMP14CYP1A2
SCHEMBL11140007 0.79 MEN1 (0.62) MEN1KMT2AMMP14MAOACASP3
SCHEMBL7034212 0.79 MEN1 (0.70) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL6420621 0.79 MEN1 (0.51) PTPRCMEN1KMT2AMMP14CYP1A2
SCHEMBL30546483 0.79 MEN1 (0.70) MEN1KMT2AMMP14CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives HUANG HSU-SHAN (TW) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives NFE2L2, NR2F2, TFAM PTPRC 3438/4885MEN1 4402/4885KMT2A 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.